Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Is FDA Reviewing A Biosimilar Marketing Application?

Nov 14 2013

• By Derrick Gingery

Related Content

FDA Sets Biosimilar Application Fees, But Is Silent On Volume Projections

Jul 31 2012

Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?

Apr 08 2013

Biosimilar Meeting Requests Increase, But FDA Cancels Some For Lack Of Data

Dec 12 2012

Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain

Sep 03 2012

Naming Rights: Biosimilar Influence Efforts Continue Before Products Take The Field

Oct 28 2013

Related Companies

Teva Pharmaceutical Industries Ltd.

Amgen, Inc.

Eli Lilly and Company

Novartis AG

Sanofi

Allergan plc

Viatris Inc.

Biocon, Ltd.

Additional Topics

United States Drug Approval Standards BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window